Related references
Note: Only part of the references are listed.Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease
Peter Bossuyt et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial
Anne S. Strik et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial
Silje Watterdal Syversen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease
Erwin Dreesen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease
Laura E. Bauman et al.
INFLAMMATORY BOWEL DISEASES (2020)
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease
Aleksejs Sazonovs et al.
GASTROENTEROLOGY (2020)
Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD
Sara Lega et al.
INFLAMMATORY BOWEL DISEASES (2019)
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients
Kathryn Clarkston et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta-analysis
Qi Wei Zhang et al.
JOURNAL OF DIGESTIVE DISEASES (2019)
Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming
Diane R. Mould et al.
AAPS JOURNAL (2018)
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
Konstantinos Papamichael et al.
GASTROENTEROLOGY (2018)
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease
Geert D'Haens et al.
GASTROENTEROLOGY (2018)
Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System
Alexander Eser et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis
David Kevans et al.
JOURNAL OF CROHNS & COLITIS (2018)
Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients
Marla C. Dubinsky et al.
AAPS JOURNAL (2017)
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Niels Vande Casteele et al.
GASTROENTEROLOGY (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window
Konstantinos Papamichael et al.
INFLAMMATORY BOWEL DISEASES (2017)
A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
Johannan F. Brandse et al.
INFLAMMATORY BOWEL DISEASES (2017)
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies
Jessica Wojciechowski et al.
AAPS JOURNAL (2017)
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results
Gil Y. Melmed et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Dashboard Systems: Pharmacokinetic/Pharmacodynamic Mediated Dose Optimization for Monoclonal Antibodies
Diane R. Mould et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease
Namita Singh et al.
INFLAMMATORY BOWEL DISEASES (2014)
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
Ingrid Ordas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Shui-Long Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
